|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
GT200500281A
(en)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
ORGANIC COMPOUNDS.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
|
EP2281813A1
(en)
|
2005-08-08 |
2011-02-09 |
Pulmagen Therapeutics (Synergy) Limited |
Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
|
|
JP5006330B2
(en)
|
2005-10-21 |
2012-08-22 |
ノバルティス アーゲー |
Human antibodies against IL13 and therapeutic uses
|
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
|
TWI374147B
(en)
|
2006-01-27 |
2012-10-11 |
Sun Pharma Advance Res Company Ltd |
Novel 11β-hydroxyandrosta-4-ene-3-ones
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
ES2384337T3
(en)
|
2006-04-21 |
2012-07-03 |
Novartis Ag |
Purine derivatives for use as adenosine A2A receptor agonists
|
|
BRPI0720799A2
(en)
|
2007-01-10 |
2014-03-11 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATION PROTEASE INHIBITORS.
|
|
JP5244904B2
(en)
|
2007-05-07 |
2013-07-24 |
ノバルティス アーゲー |
Organic compounds
|
|
EA017919B1
(en)
|
2007-12-10 |
2013-04-30 |
Новартис Аг |
Pyrazine-2 carboxamide derivatives for treating diseases which respond to the blocade of the epithelial sodium channels
|
|
CA2727196A1
(en)
|
2008-06-10 |
2009-12-17 |
Novartis Ag |
Organic compounds
|
|
ES2442343T3
(en)
|
2008-12-30 |
2014-02-11 |
Pulmagen Therapeutics (Inflammation) Limited |
Sulfonamide compounds for the treatment of respiratory disorders
|
|
US20110098311A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorported |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
WO2012116217A1
(en)
|
2011-02-25 |
2012-08-30 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
ES2882807T3
(en)
|
2011-09-16 |
2021-12-02 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
CN103946221B
(en)
|
2011-09-16 |
2016-08-03 |
诺华股份有限公司 |
For treating the heterocyclic compound of cystic fibrosis
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
WO2014192027A1
(en)
|
2013-05-28 |
2014-12-04 |
Sun Pharma Advanced Research Company Limited |
Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.
|
|
EP3007697B1
(en)
|
2013-06-14 |
2020-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Rac1 inhibitors for inducing bronchodilation
|
|
MX2016013983A
(en)
|
2014-04-24 |
2017-04-06 |
Novartis Ag |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors.
|
|
BR112016024484A2
(en)
|
2014-04-24 |
2017-08-15 |
Novartis Ag |
aminopyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
BR112016024533A8
(en)
|
2014-04-24 |
2021-03-30 |
Novartis Ag |
amino pyrazine derivatives as phosphatidylinositol 3-kinase or salt inhibitors, their use, and pharmaceutical composition and combination
|
|
CN108659090A
(en)
*
|
2017-03-31 |
2018-10-16 |
天津药业研究院有限公司 |
A kind of preparation method of 17 β-thiocarboxylic acids chloromethane esters steroidal compounds
|
|
MX2021015133A
(en)
|
2019-06-10 |
2022-01-24 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis.
|
|
US20220306617A1
(en)
|
2019-08-28 |
2022-09-29 |
Novartis Ag |
Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
|